Samples from test batches of the COVID-19 vaccine made by Siam Bioscience have passed quality testing at AstraZeneca’s designated laboratories in Europe and the United States, the company announced yesterday.
In a press release, James Teague, president of AstraZeneca (Thailand) said: “We have seen significant and promising progress in AstraZeneca’s COVID-19 vaccine development in Thailand during the past weeks.”
“First, the Thai Food and Drug Administration approved Siam Bioscience as a manufacturing facility for COVID-19 vaccine AstraZeneca.”
“Last week, the samples of COVID-19 vaccine AstraZeneca made by Siam Bioscience passed the full tests of the standards set by the Department of Medical Sciences (DMS) for requirements such as chemical composition and safety.”
“And today, I am happy to be able to inform you that the samples from the test batches of the COVID-19 vaccine made by Siam Bioscience had passed the quality testing at AstraZeneca’s designated laboratories in Europe and in the US.”
“This significant progress means that we are getting closer to deliver the first batch of the vaccine to the government of Thailand.”
According to the release, numerous safety tests and quality control measures are carried out at each step of manufacturing and distribution.
This includes completing all steps in the quality assurance process, with each batch of vaccines undergoing more than 60 different quality control tests during its journey from manufacture to vaccination.
Shortly after the announcement, the Ministry of Public Health insisted that the first batches of jabs would be given to the first group of 16 million people on 7th June.
The ministry needs to inoculate at least 70% of the population living in zones having a high level of infections in Bangkok, Chiang Mai, and Chon Buri shortly to help slow down the spread of COVID-19 throughout the country.
chiang mai one
